Search results for "Interleukin-6"

showing 10 items of 370 documents

Correlational selection on pro- and anti-inflammatory effectors.

2012

9 pages; International audience; Parasites impose a permanent threat for hosts. As a consequence, immune defenses are important for host fitness. However, the immune response can also produce self-damage and impair host fitness if not properly regulated. Effectors that up- and downregulate the immune response should, therefore, evolve in concert, and be under the action of correlational selection. To address this issue, we assessed the shape of the selection operating on pro- and anti-inflammatory effectors following an inflammatory challenge in laboratory mice. We found that selection acts on the combination of these two traits as individuals that produced large amount of pro-inflammatory …

0106 biological sciencesLipopolysaccharidesMale[ SDV.IMM.IA ] Life Sciences [q-bio]/Immunology/Adaptive immunology01 natural sciencesMiceImmunopathologyDarwinian medicine[ SDV.EE.IEO ] Life Sciences [q-bio]/Ecology environment/SymbiosisimmunopathologyGenetics0303 health sciencesEffectorFlow CytometryInterleukin-10Interleukin 10[SDV.IMM.IA]Life Sciences [q-bio]/Immunology/Adaptive immunologyIL-10CytokinesRegression AnalysisFemalemedicine.symptomGeneral Agricultural and Biological Sciences[ SDV.MP.PAR ] Life Sciences [q-bio]/Microbiology and Parasitology/Parasitologymedicine.drug_classInflammationBiology010603 evolutionary biologysurvivalAnti-inflammatory03 medical and health sciencesImmune systemImmunityGeneticsmedicineEscherichia coliAnimals[SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/ParasitologySelection GeneticEcology Evolution Behavior and SystematicsSelection (genetic algorithm)030304 developmental biologyIL-6[ SDE.BE ] Environmental Sciences/Biodiversity and Ecologyevolutionary immunologyInterleukin-6inflammationImmunology[SDE.BE]Environmental Sciences/Biodiversity and Ecology[SDV.EE.IEO]Life Sciences [q-bio]/Ecology environment/SymbiosisEvolution; international journal of organic evolution
researchProduct

Expression of NF-κB and IL-6 in oral precancerous and cancerous lesions: An immunohistochemical study.

2014

Background The purpose of this study was to evaluate the immunohistochemical expression of NF-κB and IL-6 in oral premalignant and malignant lesions and to investigate their possible correlation with the presence of subepithelial inflammation. Material and Methods Thirty two oral premalignant lesions, clinically compatible with leukoplakia or erythroplakia, were investigated. Microscopically, 11 of them showed hyperkeratosis and acanthosis (epithelial hyperplasia) and 21 showed dysplasia of varying degrees. Nine cases of OSCC and four control cases of normal oral mucosa were also included in the study. Immunohistochemical staining with NF-κB (p65) and IL-6 was performed. IL-6 and nuclear NF…

0301 basic medicineAdultMalePathologymedicine.medical_specialtyHyperkeratosisOdontologíaAcanthosis03 medical and health sciences0302 clinical medicineMedicineHumansGeneral DentistryLeukoplakiaAgedMouth neoplasmAged 80 and overErythroplakiaOral Medicine and Pathologybusiness.industryInterleukin-6ResearchNF-kappa BMiddle Aged:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseCiencias de la saludImmunohistochemistrystomatognathic diseases030104 developmental biologyOtorhinolaryngologyDysplasia030220 oncology & carcinogenesisUNESCO::CIENCIAS MÉDICASImmunohistochemistrySurgeryFemaleMouth NeoplasmsbusinessPrecancerous ConditionsImmunostainingLeukoplakiaMedicina oral, patologia oral y cirugia bucal
researchProduct

Role of Haptoglobin as a Marker of Muscular Improvement in Patients with Multiple Sclerosis after Administration of Epigallocatechin Gallate and Incr…

2021

Here, we report on the role of haptoglobin (Hp), whose expression depends on the synthesis of interleukin 6 (IL-6), related to the pathogenesis of multiple sclerosis (MS), as a possible marker of muscle improvement achieved after treatment with the polyphenol epigallocatechin gallate (EGCG) and an increase in the ketone body beta-hydroxybutyrate (BHB) in the blood. After 4 months of intervention with 27 MS patients, we observed that Hp does not significantly increase, alongside a significant decrease in IL-6 and a significant increase in muscle percentage. At the same time, Hp synthesis is considerably and positively correlated with IL-6 both before and after treatment

0301 basic medicineAdultMalemedicine.medical_specialtyepigallocatechin gallateMultiple Sclerosisbeta-hydroxybutyratemuscleinterleukin 6Pilot ProjectsEpigallocatechin gallateMicrobiologyBiochemistryCatechinArticlePathogenesis03 medical and health scienceschemistry.chemical_compound0302 clinical medicineBeta hydroxybutyrateInternal medicinemedicineHumansIn patientInterleukin 6Muscle SkeletalMolecular Biologybiology3-Hydroxybutyric AcidHaptoglobinsbusiness.industryInterleukin-6Multiple sclerosisHaptoglobinfood and beveragesMiddle Agedmedicine.diseaseQR1-502haptoglobin030104 developmental biologyEndocrinologychemistrybiology.proteinKetone bodiesFemalebusiness030217 neurology & neurosurgeryBiomarkersBiomolecules
researchProduct

Mast cells contribute to autoimmune diabetes by releasing interleukin-6 and failing to acquire a tolerogenic IL-10+ phenotype

2017

Mast cells (MCs) are innate immune cells that exert positive and negative immune modulatory functions capable to enhance or limit the intensity and/or duration of adaptive immune responses. Although MCs are crucial to regulate T cell immunity, their action in the pathogenesis of autoimmune diseases is still debated. Here we demonstrate that MCs play a crucial role in T1D pathogenesis so that their selective depletion in conditional MC knockout NOD mice protects them from the disease. MCs of diabetic NOD mice are overly inflammatory and secrete large amounts of IL-6 that favors differentiation of IL-17-secreting T cells at the site of autoimmunity. Moreover, while MCs of control mice acquire…

0301 basic medicineBlood GlucoseAutoimmune diabeteAutoimmunityNodmedicine.disease_causeT-Lymphocytes RegulatoryAutoimmunityImmune toleranceSettore MED/13 - EndocrinologiaMiceAutoimmune diabetes0302 clinical medicineMice Inbred NODImmunology and AllergyNOD miceMice KnockoutInterleukin-17Forkhead Transcription FactorsFlow CytometryImmunohistochemistryhumanitiesInterleukin-10Interleukin 10Tumor necrosis factor alphaImmunologySettore MED/50 - Scienze Tecniche Mediche ApplicateMice TransgenicLaser Capture MicrodissectionReal-Time Polymerase Chain Reactionbehavioral disciplines and activities03 medical and health sciencesIslets of LangerhansImmune systemChymasesmedicineAnimalsInflammationInnate immune systembusiness.industryInterleukin-6Immune toleranceSettore MED/46 - Scienze Tecniche di Medicina di LaboratorioAutoimmune diabetes; Immune tolerance; Interleukin-10; Interleukin-6; Mast cells030104 developmental biologyDiabetes Mellitus Type 1ImmunologyMast cellsTh17 CellsMast cells; Autoimmune diabetes; Interleukin-6; Immune tolerance; Interleukin-10business030215 immunology
researchProduct

Oleanolic acid improves diet-induced obesity by modulating fat preference and inflammation in mice.

2018

Obesity, triggered by high-fat diet (HFD), is associated to altered gustatory perception of dietary lipids. Oleanolic acid (OLA), a triterpene, has been reported to exert anti-obesity effects in animal models. Hence, we investigated the role of OLA in the modulation of oro-sensory perception of lipids in control and HFD-induced obese mice. As expected, OLA-treated obese mice exhibited a decrease in body, liver, and visceral adipose tissue weights. OLA treatment improved glucose tolerance, insulin level, plasma lipopolysaccharide (LPS), and hepatic cholesterol and triglyceride concentrations. OLA-treated obese mice exhibited higher fat preference compared to untreated obese mice, probably du…

0301 basic medicineCD36 AntigensLipopolysaccharidesmedicine.medical_specialtyCD36medicine.medical_treatmentInterleukin-1betaAdipose tissue030209 endocrinology & metabolismInflammationDiet High-FatDiet MediterraneanWeight GainBiochemistry03 medical and health scienceschemistry.chemical_compound0302 clinical medicineTaste receptorInternal medicinemedicineAnimalsInsulinObesityRNA MessengerOleanolic AcidCarbohydrate-responsive element-binding proteinOleanolic acidInflammationbiologyTriglycerideChemistryInterleukin-6InsulinLipogenesisGeneral MedicineGlucose Tolerance TestTaste BudsMice Inbred C57BL030104 developmental biologyEndocrinologyAdipose TissueLiverbiology.proteinCalciumFemalemedicine.symptomInflammation MediatorsBiochimie
researchProduct

1-ethyl-3-(6-methylphenanthridine-8-il) urea modulates TLR3/9 activation and induces selective pro-inflammatory cytokine expression in vitro.

2017

We have previously demonstrated the nucleic acid binding capacity of phenanthridine derivatives (PHTs). Because nucleic acids are potent inducers of innate immune response through Toll-like receptors (TLRs), and because PTHs bear a structural resemblance to commonly used synthetic ligands for TLR7/8, we hypothesized that PHTs could modulate/activate immune response. We found that compound M199 induces secretion of IL-6, IL-8 and TNFα in human PBMCs and inhibits TLR3/9 activation in different cellular systems (PBMCs, HEK293 and THP-1 cell lines).

0301 basic medicineClinical BiochemistryPharmaceutical ScienceDown-RegulationBiochemistryCell Line03 medical and health sciences0302 clinical medicineImmune systemDrug DiscoveryHumansImmunologic FactorsUreaSecretionReceptorMolecular BiologyInnate immune systemChemistryInterleukin-6Tumor Necrosis Factor-alphaOrganic ChemistryInterleukin-8Interferon-alphaTLR7Molecular biologyphenantridines ; TLR ; PBMCs ; cytokines ; immunomodulationIntercalating AgentsPhenanthridinesToll-Like Receptor 3030104 developmental biologyOligodeoxyribonucleotidesToll-Like Receptor 9TLR3Nucleic acidMolecular MedicineTumor necrosis factor alpha030215 immunologySignal TransductionBioorganicmedicinal chemistry letters
researchProduct

Hyperosmolarity and Benzalkonium Chloride Differently Stimulate Inflammatory Markers in Conjunctiva-Derived Epithelial Cells in vitro

2017

Tear hyperosmolarity is known to cause ocular surface inflammation in dry eye syndrome. Benzalkonium chloride (BAK), an eyedrop preservative, is known to induce dry eye in long-term-treated patients. Analyzing the modulation of the proinflammatory potential of hyperosmolarity in the presence of BAK on the conjunctiva could give new insights into the effect of this preservative on the disease. In a hyperosmolar model on a conjunctiva-derived cell line, and in the presence of BAK, we evaluated key inflammatory markers [CCL2, IL-8, IL-6, macrophage migration inhibitory factor (MIF) and intercellular adhesion molecule (ICAM)-1] as well as the osmoprotectant element nuclear factor of activated T…

0301 basic medicineConjunctivaCell Survival[SDV]Life Sciences [q-bio]Enzyme-Linked Immunosorbent AssayInflammationPharmacologyCell LineProinflammatory cytokine03 medical and health sciencesCellular and Molecular NeuroscienceBenzalkonium chloride0302 clinical medicineNFAT5medicineHumansChemokine CCL2ComputingMilieux_MISCELLANEOUSInterleukin-6ChemistryInterleukin-8Osmolar ConcentrationPreservatives PharmaceuticalEpithelial CellsNFATGeneral MedicineAnatomyConjunctivitisIntercellular Adhesion Molecule-1Intercellular adhesion moleculeSensory Systems[SDV] Life Sciences [q-bio]Ophthalmology030104 developmental biologymedicine.anatomical_structure030221 ophthalmology & optometryMacrophage migration inhibitory factorbiological phenomena cell phenomena and immunitymedicine.symptomBenzalkonium CompoundsConjunctivaBiomarkersmedicine.drug
researchProduct

Advances in the treatment of cutaneous lupus erythematosus.

2016

Lupus erythematosus (LE) is a multifactorial autoimmune disease with clinical manifestations of differing severity which may present with skin manifestations as primary sign of the disease (cutaneous lupus erythematosus, CLE) or as part of a disease spectrum (systemic lupus erythematosus, SLE). To date, no drugs are approved specifically for the treatment of CLE and only single agents have been applied in randomized controlled trials. Therefore, topical and systemic agents are used “off-label”, primarily based on open-label studies, case series, retrospective analyses, and expert opinions. In contrast, several agents, such as hydroxychloroquine, chloroquine, cyclophosphamide, azathioprine,…

0301 basic medicineCyclophosphamideDiscoid lupus erythematosusAzathioprineAntibodiesEtanerceptPolyethylene Glycols03 medical and health sciencesLupus Erythematosus DiscoidRheumatologyimmune system diseasesChloroquineMedicineHumansLupus Erythematosus SystemicMolecular Targeted TherapyPrecision Medicineskin and connective tissue diseasesRandomized Controlled Trials as TopicB-LymphocytesLupus erythematosusbusiness.industryInterleukin-6Anti-Inflammatory Agents Non-SteroidalHydroxychloroquinemedicine.diseaseBelimumab030104 developmental biologyImmunologyInterferonsbusinessBiomarkersAnti-SSA/Ro autoantibodiesmedicine.drugSignal TransductionLupus
researchProduct

Preventive effects of guanosine on intestinal inflammation in 2, 4-dinitrobenzene sulfonic acid (DNBS)-induced colitis in rats

2018

Background: Guanosine, a guanine-based purine, is an extracellular signaling molecule exerting anti-inflammatory and antioxidative effects in several in vivo and in vitro injury models. We aimed to investigate its protective effects on 2, 4-dinitrobenzene sulfonic acid (DNBS)-induced colitis in rat. Methods: Rats were divided into five groups and colitis was induced by intracolonic instillation of DNBS (15 mg/rat). Guanosine (4 or 8 mg/kg) was administered for 6 days i.p. starting the day of the colitis induction. Body weight loss, stool consistency, colon weight/length, histological analysis, myeloperoxidase activity (MPO) and pro-inflammatory cytokine levels were assessed. Immunoblotting …

0301 basic medicineDNBS ratColonmedicine.medical_treatmentInterleukin-1betaImmunologyAnti-Inflammatory AgentsGuanosineInflammationPharmacologySettore BIO/09 - FisiologiaInflammatory bowel diseaseAntioxidantsInflammatory bowel disease03 medical and health scienceschemistry.chemical_compound0302 clinical medicineIn vivomedicineAnimalsPharmacology (medical)Intestinal MucosaRats WistarColitisPurineInflammationPharmacologychemistry.chemical_classificationReactive oxygen speciesGuanosineInterleukin-6Tumor Necrosis Factor-alphaNF-kappa BColitismedicine.diseaseRats030104 developmental biologyCytokinechemistryCytokinesDinitrofluorobenzeneTumor necrosis factor alphamedicine.symptomReactive Oxygen Species030217 neurology & neurosurgeryInflammopharmacology
researchProduct

A Pharmacological Update of Ellagic Acid.

2018

Este artículo se encuentra disponible en la página web de la revista en la siguiente URL: https://www.thieme-connect.com/products/ejournals/pdf/10.1055/a-0633-9492.pdf This is a pre-print of an article published in Ríos, JL., Giner, RM., Marín, M. and Recio, MC. (2018). A pharmacological update of ellagic acid. Planta Medica, vol. 84, n. 15, pp. 1068-1093. The final authenticated version is available online at: https://doi.org/10.1055/a-0633-9492 Este es el pre-print del siguiente artículo Ríos, JL., Giner, RM., Marín, M. and Recio, MC. (2018). A pharmacological update of ellagic acid. Planta Medica, vol. 84, n. 15, pp. 1068-1093 que se ha publicado de forma definitiva en https://doi.org/10…

0301 basic medicineEllagic acid - Pharmacokinetics.Antioxidantmedicine.medical_treatmentMetaboliteInterleukin-1betaAnti-Inflammatory AgentsPharmaceutical ScienceApoptosisPharmacologyProtective AgentsProteína quinasa.NeuroprotectionAntioxidantsAnalytical Chemistry03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEllagic AcidGlycationDrug DiscoverymedicineHumansProtein kinases.Cell ProliferationPharmacologyMetabolic SyndromeAldose reductaseInterleukin-6Tumor Necrosis Factor-alphaMetabolismo - Trastornos.Organic ChemistryNF-kappa BLipid metabolismAtherosclerosisEllagic acid - Physiological effect.NeuroprotectionMetabolism disorder030104 developmental biologyComplementary and alternative medicinechemistryÁcido elágico - Efectos fisiológicos.Antioxidantes.Ácido elágico - Farmacocinética.030220 oncology & carcinogenesisMolecular MedicineMetabolism - Disorders.Antioxidants.Ellagic acidPlanta medica
researchProduct